Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily treatment-experienced people with multidrug resistant HIV
MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ('Theratechnologies' or the 'Company') (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in reducing HIV RNA to undetectable levels in heavily treatment-experienced (HTE) patients with multidrug resistant HIV.
In a poster session at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, Calif., investigators from the Prospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) reported that patients treated with regimens containing ibalizumab achieved undetectable HIV viral load levels at similar rates as those receiving non-ibalizumab-containing regimens, despite displaying characteristics indicative of more severe HIV disease at baseline.
'The availability of long-term injectable therapies has not eliminated the phenomenon of multidrug resistance, and heavily treatment-experienced people with HIV deserve fully suppressive antiretroviral regimens that can help them establish and maintain virologic control,' stated presenting author Smitha Gudipati, MD, an infectious disease specialist at Henry Ford Hospital in Detroit, Mich. 'We are therefore encouraged to see such impressive reductions in viremia in patients whose regimens include ibalizumab, despite having lower CD4 counts and higher viral loads at baseline than the non-ibalizumab control group.'
Theratechnologies previously announced the study design and baseline characteristics of participants in PROMISE-US (ClinicalTrials.gov identifier: NCT05388474), a phase 4, multicenter, retrospective and prospective, observational, non-interventional registry study. The trial is designed to assess risk factors and predictors of virologic and immunologic response in HTE people with HIV (PWH) and specific sub-populations. Its primary objective is to evaluate the long-term efficacy and durability of ibalizumab, a CD4-directed post-attachment inhibitor of HIV, in combination with other antiretroviral therapies by comparing the clinical outcomes of patients receiving ibalizumab (Cohort 2) versus matched patients not receiving ibalizumab (Cohort 1).
At CROI, the PROMISE-US investigators presented an interim, unmatched subgroup analysis comprising 112 participants, of whom 70 were enrolled in Cohort 1 and 42 in Cohort 2. At baseline, 27 of participants in Cohort 1 and 25 in Cohort 2 were viremic, defined as viral load above 50 RNA copies/mL (39% and 57%, respectively; p=0.0279). Three-quarters (74%) of participants in Cohort 1 who had baseline viremia had more than 200 CD4 T-cells/mm3 at baseline, compared to only 44% of those in Cohort 2 who were viremic at baseline (p=0.0376).
Among those with baseline viremia, 50% of Cohort 1 participants and 47% in Cohort 2 achieved undetectable viral load (≤50 RNA copies/mL) after six months of treatment (p=0.873). At 12 months, viral load was undetectable in 53% of Cohort 1 participants and in 42% of those in Cohort 2 (p=0.0.524). Ibalizumab was well-tolerated with no infusion reactions reported and no discontinuation of treatment by participants in Cohort 2 due to a treatment emergent adverse event.
'The PROMISE-US trial is the first registry to capture long-term clinical outcomes for highly treatment-experienced patients with multidrug-resistant HIV in a real-world setting and in the US specifically,' commented Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. 'The data presented today suggest that ibalizumab can be a critical component of therapeutic regimens in the modern antiretroviral era. We look forward to validating these interim findings as we continue to enroll and monitor patients in this ongoing study.'
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, the 'Forward-Looking Statements'), within the meaning of applicable securities laws, that are based on our management's beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as 'may', 'will', 'should', 'could', 'promising', 'would', 'outlook', 'believe', 'plan', 'envisage', 'anticipate', 'expect' and 'estimate', or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the long-term safety and efficacy of ibalizumab, the effect of ibalizumab on the reductions of viremia and the use of ibalizumab as a component of therapeutic regimens in the modern antiretroviral era. Forward-looking statements involve a number of assumptions, risks and uncertainties. Some of these assumptions include, but are not limited to, the fact that patients receiving ibalizumab will achieve undetectable HIV viral load levels. The Company refers current and potential investors to the 'Risk Factors' section of its Annual Information Form filed under the Company's Form 20-F dated February 26, 2025 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies' public filings for the risks associated with the business of Theratechnologies. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company's expectations as of that date.
The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Media inquiries:Julie SchneidermanSenior Director, Communications & Corporate Affairscommunications@theratech.com1-514-336-7800
Investor Inquiries:Joanne ChoiSenior Director, Investor Relationsjchoi@theratech.com1-551-261-0401Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The Food and Drug Administration (FDA) approved ORLYNVAH™ for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH™ is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies. Sixty percent of women experience a urinary tract infection in their lifetime and 44% experience three or more episodes annually. It is the most common outpatient infection in women in the United States, and resistance continues to increase. According to a 2024 U.S. study in approximately 150,000 patients with uncomplicated UTIs: 57% of initial infections were resistant to at least one antibiotic class; and 13% were resistant to three or more. Without new, safe and effective oral therapies, resistant uUTIs are expected to inflate healthcare costs and may lead to poor patient outcomes in the U.S., including the need for additional courses of therapy, emergency room visits or hospitalizations, all of which underscore the urgent need for innovation in this space. 'The availability of ORLYNVAH™ is tremendous news for clinicians and patients alike,' said Marjorie Golden, MD, FIDSA, Site Chief, Infectious Disease, St. Raphael Campus Yale New Haven Hospital. 'The launch of ORLYNVAH™ provides a new treatment option with impressive efficacy data to treat appropriate adult women suffering from difficult-to-treat uUTIs.' Dr. Golden added, 'For patients who currently have limited treatment options, ORLYNVAH™ provides a long overdue oral alternative that allows for treatment in the community. This paradigm shift in the management of patients with uUTI will not only reduce emergency department visits and hospital admissions, but it will also favorably impact patients' quality of life.' 'Our mission is to create new antibiotics for patients and to be a treatment alternative to address substantial unmet medical needs in the community,' said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. 'For many people with multidrug-resistant uUTIs, options have been exhausted. We're proud to introduce ORLYNVAH™—the first oral penem ever approved by the FDA—giving clinicians and patients a much-needed new therapy.' To support patient access, Iterum Therapeutics is launching a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25. For more information about ORLYNVAH™, including full prescribing information, please visit Uncomplicated urinary tract infections (uUTIs) are a common bladder infection typically confined to the lower urinary tract in otherwise healthy women with no structural abnormalities of the urinary tract—caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. About Iterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit About ORLYNVAH™ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. Cautionary Note Regarding Forward-looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™ and the success of Iterum's commercialization of ORLYNVAH™ in the U.S. In some cases, forward-looking statements can be identified by words such as 'may,' 'believes,' 'intends,' 'seeks,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'should,' 'assumes,' 'continues,' 'could,' 'would,' 'will,' 'future,' 'potential' or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including Iterum's ability to maintain and continue to build a sales force for the commercialization of ORLYNVAH™ in the U.S., the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if the commercialization of ORLYNVAH™ in the U.S. is unsuccessful, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, the potential impact of resistant uUTIs on healthcare costs and medical outcomes for uUTI patients in the U.S., Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PRESS CONTACTJennifer PerciballiOak+Cannon PR for Iterumjennifer@ Investor RelationsJudy MatthewsChief Financial Officer Iterum Therapeutics 312-778-6073IR@
Yahoo
4 hours ago
- Yahoo
Bluesight introduces ShortageCheck to manage drug inventories in hospitals
Hospital intelligence solutions provider Bluesight has launched ShortageCheck technology designed to assist health systems and hospitals in tracking, forecasting and managing drug inventories. ShortageCheck integrates real-time inventory data, predictive analytics, and collaborative planning tools into a comprehensive platform. This innovation is poised to ensure that caregivers and patients have uninterrupted access to essential medications. Monitoring over 20 real-time market signals, encompassing demand spikes and fulfilment delays, ShortageCheck provides coverage across more than 2,500 acute care facilities across the US. It identifies early warning signs of drug shortages, offering up to a 90-day lead time, with an average of 42 days, allowing healthcare institutions to prepare and adapt their inventory management strategies. By assessing levels of inventory, usage rates along with days-on-hand, the platform offers in-depth insights into the potential impact of each shortage. This enables organisations to evaluate risk, prioritise responses and leverage ShortageCheck's communication tools for cross-team coordination and planning. Bluesight CEO and co-founder Kevin MacDonald said: 'Shortage management has been one of, if not the most critical, pain point for our customers over the last six years. When drug shortages hit without warning, it forces teams to scramble for alternatives, and patient care ultimately suffers. 'With improving health system operations as our top priority, the launch of ShortageCheck marks a significant milestone in ensuring customers have the solutions needed to get ahead of shortages before they hit, preserving labour hours and costs during a time when drug costs are rising, staff shortages persist, and medicare reimbursement changes are on the horizon.' ShortageCheck is part of the hospital intelligence solutions suite of Bluesight, which includes CostCheck, KitCheck, 340BCheck, ControlCheck and PrivacyPro. These tools collectively offer hospitals the capability to restock inventory quicker, reduce drug expenditure, streamline audit preparations, pinpoint drug diversion more effectively, and save time in protecting patient privacy. This January, Bluesight expanded its capabilities by acquiring Protenus, a healthcare compliance analytics platform provider. "Bluesight introduces ShortageCheck to manage drug inventories in hospitals" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Wire
5 hours ago
- Business Wire
Wisdom, the AI-Powered Dental Revenue Cycle Management Platform, Raises $28M to Accelerate Product Innovation and Capitalize on Rapid Growth
SAN FRANCISCO--(BUSINESS WIRE)--AI in revenue cycle management has become top of mind across the healthcare industry, but when it comes to the dental market, dentists are lacking the modern tools used by their medical counterparts. That's the problem that AI-powered dental RCM platform, Wisdom, is on a mission to solve. The company announced today the successful completion of its $21M Series A capital raise led by Permanent Capital Ventures (PCV), a venture capital firm that partners with founders to build go-to-market engines for enterprise scale. Aquiline, a private investment firm specializing in financial services and technology, joined the round, alongside existing investor and Co-Founder, Juxtapose, a leading creation-oriented investment firm. Juxtapose followed their recent $7M Seed investment, reaffirming the firm's commitment to Wisdom's continued growth and innovation. This funding brings Wisdom's total capital raised to $28M since its founding in 2023. The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Share The overwhelming majority of independent practices and small dental groups in America struggle with the administrative burden of running a profitable business, leaving over $20 billion of earned revenue uncollected despite spending billions of dollars on salaries for in-house revenue management. Wisdom, which has already collected hundreds of millions of dollars for its clients and saved them up to 50% of collection costs, takes a highly differentiated approach to administrative workflows by bringing AI agents and human experts together to maximize revenue collections, predictability, transparency and patient satisfaction, thereby freeing dentists and their staff to focus on delivering outstanding patient care. Since its inception, Wisdom has rapidly expanded by combining advanced, proprietary AI-driven technology with US-based billing experts. This unique approach has propelled Wisdom to achieve exceptional client satisfaction, underscored by a consistently high Net Promoter Score of 73 and strong organic growth. Over 50% of Wisdom's signed deals still come through referrals. Wisdom was awarded Top Dental Billing Company by Healthcare Business Review earlier this year and was named a 2025 Dental Innovator Award winner by DentalIQ for its AI-assisted dental billing service. Wisdom is led by CEO Stoyan Kenderov, an accomplished technologist, product leader and executive with over 25 years of success building new products and transforming organizations into customer-obsessed teams that drive growth and profitability, most recently as COO of business payments platform Plastiq. Prior to his time at Plastiq, Stoyan held senior leadership roles at LendingClub, Intuit, Quicken, and many other international technology companies. Stoyan is joined by Wisdom Co-Founder and Chief Dental Billing Officer Ashley Bond, who previously founded and led the award-winning nationwide billing service, Bond Dental Billing. 'We are thrilled to partner with PCV and Aquiline as we continue our mission to transform dental billing and revenue management,' said Kenderov. 'Their proactive approach and expertise in building scalable enterprises align perfectly with our vision to significantly enhance financial outcomes and operational efficiency for dental practices.' PCV's investment in Wisdom reflects the firm's strategy of supporting innovative startups poised for transformational growth. 'Wisdom has created an impressive track record by uniquely integrating AI technologies with deep industry expertise,' said Mike Gamson, Co-Founder and Managing Partner at Permanent Capital Ventures. 'We see immense potential in their ability to scale and redefine revenue management solutions in the dental sector and beyond.' Aquiline has a history of building scaled revenue cycle management businesses, and this investment in Wisdom marks the firm's second investment supporting the dental industry. 'While we continue to see significant innovation across dental, the market is filled with point solutions and generally lacks modern, end-to-end platforms, especially across the rev cycle process,' said Dante La Ruffa, Partner at Aquiline. 'We believe that Stoyan and his team are reimagining the future of dentistry, starting with the key pain points that have historically inhibited dentists from maximizing their time with patients.' This funding will enable Wisdom to further enhance its technology platform, accelerate market expansion, and continue building out its exceptional team to better serve dental offices of all sizes - from private practices to multi-location dental groups across the country. 'The opportunity to use technology to help dentists build and run their businesses more effectively is immense. Stoyan and his team have moved quickly but thoughtfully to build a solution which really moves the needle for dentists while preserving the value of human expertise,' said Andy Stein, Partner at Juxtapose. For more information about Wisdom and its innovative dental billing solutions, please visit About Juxtapose Juxtapose is a creation-oriented investment firm building and funding industry-defining technology companies. Juxtapose's concept development and investment process is focused on multi-decade opportunities in complex industries that leverage the team's expertise in software and technology, human-centered design, commercial strategy, executive talent assessment, and private capital markets. Juxtapose has built and led the financing of companies across software, healthcare, and tech-enabled services that have raised over $1B of external, follow-on private capital. Founded in 2016, Juxtapose now has over $1B AUM. About Permanent Capital Ventures Permanent Capital Ventures is an expansion stage venture capital firm that partners with extraordinary founders building AI application businesses. We lean in with unique go-to-market expertise in the moments after product-market fit has been established to help unlock the path to enterprise scale. About Aquiline Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management across the firm's three strategies in private equity, venture, and credit. Additional information is available on the firm's website: Aquiline Capital Partners LP ('Aquiline') is a private investment firm based in New York, London, and Philadelphia, that is dedicated to financial services and technology. As of June 30, 2025, Aquiline has approximately $13 billion of assets under management and has deployed approximately $7.4 billion of capital across the firm's three strategies in private equity, venture, and credit.
